Our Mission:
Accelerating the prevention and cure of myeloma and improving
the quality of life for patients and families
I am a...
About Multiple Myeloma
Multiple myeloma starts in the bone marrow plasma cells. It weakens the immune system and can affect many parts of the body by causing the bone marrow to create dysfunctional antibodies and plasma cells. Living with or treating this disease means making complicated decisions, and this requires searching for reliable, current information on multiple myeloma.
How Can the International Myeloma Foundation Help?
The International Myeloma Foundation (IMF) connects people to what matters most — research that pushes the field forward, education that clarifies complex topics, support tailored to individual needs, and advocacy that amplifies every voice. Patients, care partners, healthcare professionals, and researchers can access the knowledge, resources, and community they need from the IMF to navigate life with myeloma.
This week’s blog covers frequently asked questions (FAQs) on the FDA accelerated approval of ZENBEXUS™ (iberdomide), in combination with Darzalex Faspro® (daratumumab and hyaluronidase-fihj) and dexamethasone as treatment for adults with relapsed/refractory myeloma (RRMM). Iberdomide is the first cereblon-modulating protein degrader (CELMoD) for multiple myeloma that received accelerated approval from the FDA.
An accelerated approval is a U.S. FDA regulatory pathway that can allow approval of a drug for a serious condition based on evidence involving a surrogate endpoint that is considered reasonably likely to predict clinical benefit. READ THE BLOG.
The IMF will be holding the Asian Myeloma Network (AMN) awards ceremony on Saturday, October 17, during the 10th Annual AMN Summit in Shanghai, China, from October 15-18, 2026. This year's 10th Annual AMN Summit will be Asia's largest gathering ever of myeloma specialists, along with patients and caregivers.
Launched in 2023 by the AMN Executive Committee, the Asian Myeloma Network Distinguished Service Award recognizes and honors the lifelong achievements of deserving AMN myeloma specialists, who have made a considerable impact in the field of myeloma research, clinical trials, and patient support. This year's AMN Distinguished Service Awardee is Wee Joo Chng, MB ChB, PhD, FRCP (UK), FRCPath (UK), FAMS. READ THE PRESS RELEASE.
Join the International Myeloma Foundation for a FREE webinar: "Living Well with Myeloma: Beyond Survival: Embracing Sexuality Through the Cancer Journey" on October 20, 2026, at 4 p.m. PT | 5 p.m. MT | 6 p.m. CT | 7 p.m. ET. Monika Brown, MSN, WHNP-BC, a Women’s Health Nurse Practitioner with 14 years of specialized experience in gynecologic oncology, will explore the many ways cancer and its treatment can affect sexual health and intimacy. REGISTER NOW.
La próxima reunión del grupo de apoyo en español Las Voces de Mieloma se llevará a cabo el martes 20 de octubre, de 10:00 a 11:00 a. m. (hora del Pacífico). El ponente será el Dr. Mauricio Villegas Fortuny, médico cirujano especialista en Medicina Interna y Hematología Clínica. El tema de la reunión será el tratamiento de primera línea para el mieloma múltiple y las novedades sobre las combinaciones de terapias biespecíficas y CAR-T. REGÍSTRESE AQUÍ.
When you volunteer to organize a community fundraiser for the IMF, you receive support and guidance from the IMF's Development Team. Whether it's a 5K Walk/Run, a bake sale, or a simple letter-writing campaign, we're here to help you.
